Article
Cover
RJAS Journal Cover Page

RGUHS Nat. J. Pub. Heal. Sci Vol No: 11 Issue No: 1  pISSN: 2249-2194

Article Submission Guidelines

Dear Authors,
We invite you to watch this comprehensive video guide on the process of submitting your article online. This video will provide you with step-by-step instructions to ensure a smooth and successful submission.
Thank you for your attention and cooperation.

Original Article
Prof. M.A. Siddiqui1, Mohd. Aleemuddin Quamri2, S.M. Raeesuddin3,

1Prof. M.A. Siddiqui, Dept of Moalajat, National Institute of Unani Medicine, Bangalore

2Mohd. Aleemuddin Quamri, Dept of Moalajat, National Institute of Unani Medicine, Bangalore

3S.M. Raeesuddin, Dept of Moalajat, National Institute of Unani Medicine, Bangalore

Received Date: 2012-09-01,
Accepted Date: 2012-10-01,
Published Date: 2012-10-31
Year: 2012, Volume: 2, Issue: 2, Page no. 23-26,
Views: 425, Downloads: 8
Licensing Information:
CC BY NC 4.0 ICON
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0.
Abstract

Hypertension is a disorder of circulatory regulation characterized by persistent, non physiologic elevation of systemic blood pressure. It is the leading cause of death in the world. In India and its surrounding countries. awareness level of this disease is < 45%, out of them only hatf of the sufferers are on treatment, with poor adequacy of control of blood pressure. 90 to 95% of hypertensive patients suffer from Primary hypertension. in which a single reversible cause of the elevated blood pressure cannot be identified. The dinical features of target organ damage due to Hypertension correspond with the clinical features of Imtila. Hgamat Bil Shurt is a prescribed by Unani physicians to treat the Imtlja. To evaluate the efficacy of Hijamat Bil Shurt in the management of primary hypertension, an open randomized standard control trial conducted in 50 cases. After obtaining informed consent 30 patients of test group were subjected to the test procedure (Hijamat Bil Shurt ) once only, and 20 patients of control group were treated with standard control 25 mg of Atenolot once daily. both groups were followed up for 60 days. Al the cases were assessed for subjective and objective parameters. The results were analyzed statistically. The test group exhibited statistically significant reduction in SBP at P<0.05, P<0.001with respect to 0 day of test and p<0.05, P<0.01 with respect to O day of control and DBP at P<0.001 , p<0.001 with respect to 0 day of test and P<0.05 with respect to 0 day of control. No adverse effects were observed during and after trial.

<p>Hypertension is a disorder of circulatory regulation characterized by persistent, non physiologic elevation of systemic blood pressure. It is the leading cause of death in the world. In India and its surrounding countries. awareness level of this disease is &lt; 45%, out of them only hatf of the sufferers are on treatment, with poor adequacy of control of blood pressure. 90 to 95% of hypertensive patients suffer from Primary hypertension. in which a single reversible cause of the elevated blood pressure cannot be identified. The dinical features of target organ damage due to Hypertension correspond with the clinical features of Imtila. Hgamat Bil Shurt is a prescribed by Unani physicians to treat the Imtlja. To evaluate the efficacy of Hijamat Bil Shurt in the management of primary hypertension, an open randomized standard control trial conducted in 50 cases. After obtaining informed consent 30 patients of test group were subjected to the test procedure (Hijamat Bil Shurt ) once only, and 20 patients of control group were treated with standard control 25 mg of Atenolot once daily. both groups were followed up for 60 days. Al the cases were assessed for subjective and objective parameters. The results were analyzed statistically. The test group exhibited statistically significant reduction in SBP at P&lt;0.05, P&lt;0.001with respect to 0 day of test and p&lt;0.05, P&lt;0.01 with respect to O day of control and DBP at P&lt;0.001 , p&lt;0.001 with respect to 0 day of test and P&lt;0.05 with respect to 0 day of control. No adverse effects were observed during and after trial.</p>
Keywords
Primary Hypertension, Unani, Imtila, Hijamat Bil Shun, Atenelol.
Downloads
  • 1
    FullTextPDF
Article

None

Supporting File
No Pictures
References

None

HealthMinds Logo
RGUHS Logo

© 2024 HealthMinds Consulting Pvt. Ltd. This copyright specifically applies to the website design, unless otherwise stated.

We use and utilize cookies and other similar technologies necessary to understand, optimize, and improve visitor's experience in our site. By continuing to use our site you agree to our Cookies, Privacy and Terms of Use Policies.